Literature DB >> 16893579

Pulmonary function at peak exercise in patients with chronic heart failure.

Ourania Papazachou1, Maria Anastasiou-Nana, Dimitrios Sakellariou, Antonia Tassiou, Stavros Dimopoulos, John Venetsanakos, George Maroulidis, Stavros Drakos, Charis Roussos, Serafim Nanas.   

Abstract

BACKGROUND: Various respiratory abnormalities are associated with chronic heart failure (CHF). However, changes in inspiratory capacity (IC) and breathing pattern from rest to exercise in patients with CHF have not been thoroughly investigated in these patients.
MATERIALS AND METHODS: Seventy seven (66 male/11 female) patients with clinical stable CHF (age: 52+/-11 years) were studied. All the patients underwent pulmonary function tests, including measurements of IC and maximal inspiratory pressure (Pimax) at rest and then a maximal cardiopulmonary exercise testing (CPET) on a treadmill. During the CPET, IC was measured every 2 min. Pimax was measured again after the end of CPET.
RESULTS: Percent predicted forced expiratory volume in 1 s (FEV1) was 91+/-12, %predicted forced vital capacity (FVC) was 92+/-13, %FEV1/FVC was 81+/-4, and %predicted IC was 85+/-18. Peak exercise IC was lower than resting (2.4+/-0.6 vs. 2.6+/-0.6 l, p<0.001). Analysis of variance between Weber's groups revealed statistically significant differences in peak exercise IC (p<0.001), VE/VCO2slope (p<0.001), resting Pimax (p=0.005) and post-exercise Pimax (p<0.001). At rest, there was a statistically significant difference in end-tidal CO2 (P(ETCO2)) (p=0.002), in breathing frequency (p=0.004), in inspiratory time (Ti) (p=0.04) and in total respiratory time (T(Tot)) (p=0.004) among Weber's groups. At peak exercise there was a statistically significant decrease in minute ventilation (VE) (p<0.001), tidal volume (VT) (p<0.001), respiratory cycle (VT/TI) (p<0.001) and P(ETCO2) (p<0.001). Peak IC was correlated with peak VO2 (r=0.72, p<0.001), anaerobic threshold (r=0.71, p<0.001), VO2/t slope (r=0.54, p<0.0001), and post-exercise Pimax (r=0.62, p<0.001).
CONCLUSIONS: In patients with CHF, peak exercise IC is reduced in parallel with disease severity, which is probably due to respiratory muscle dysfunction.

Entities:  

Mesh:

Year:  2006        PMID: 16893579     DOI: 10.1016/j.ijcard.2006.04.091

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Ventilatory anaerobic thresholds of individuals recovering from traumatic brain injury compared with noninjured controls.

Authors:  William E Amonette; Kurt A Mossberg
Journal:  J Head Trauma Rehabil       Date:  2013 Sep-Oct       Impact factor: 2.710

2.  Maximum inspiratory pressure, a surrogate parameter for the assessment of ICU-acquired weakness.

Authors:  Georgios Tzanis; Ioannis Vasileiadis; Dimitrios Zervakis; Eleftherios Karatzanos; Stavros Dimopoulos; Theodore Pitsolis; Elli Tripodaki; Vasiliki Gerovasili; Christina Routsi; Serafim Nanas
Journal:  BMC Anesthesiol       Date:  2011-06-26       Impact factor: 2.217

3.  Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension.

Authors:  Manuel J Richter; Henning Gall; Gesa Wittkämper; Werner Seeger; Eckhard Mayer; Hossein A Ghofrani; Stefan Guth; Frank Reichenberger
Journal:  Pulm Circ       Date:  2017-05-12       Impact factor: 3.017

Review 4.  Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure.

Authors:  Katarzyna Kulej-Lyko; Piotr Niewinski; Stanislaw Tubek; Piotr Ponikowski
Journal:  Front Physiol       Date:  2022-04-14       Impact factor: 4.755

5.  Ventilatory constraints influence physiological dead space in heart failure.

Authors:  Joshua R Smith; Thomas P Olson
Journal:  Exp Physiol       Date:  2018-11-23       Impact factor: 2.969

6.  Pulmonary function differences in patients with chronic right heart failure secondary to pulmonary arterial hypertension and chronic left heart failure.

Authors:  Wei-Hua Liu; Qin Luo; Zhi-Hong Liu; Qing Zhao; Qun-Ying Xi; Hai-Feng Xue; Zhi-Hui Zhao
Journal:  Med Sci Monit       Date:  2014-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.